Potentially anti-competitive practices, such as reverse payment agreements and strategic patenting, risk allowing pharmaceutical companies to block the entry of generic and innovative medicines, stifling competition and harming consumers. Such practices create particular challenges for developing countries. Policy coherence between the IP system and competition law must be strengthened in order to promote innovation and access to health technologies.
|Pages (from-to)||661 - 667|
|Journal||European Intellectual Property Review|
|Publication status||Published - 16 May 2016|